Trial Profile

A Phase 1b/2a Study to Assess the Safety, Pharmacokinetics, and Preliminary Efficacy of TU2218, an Oral TGFβR Serine/Threonine Kinase Inhibitor, Administered in Combination With Pembrolizumab in Patients With Advanced Solid Tumors

Status: Recruiting

Phase of Trial: Phase I/II

Latest Information Update: 02 Apr 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs NCE 401 (Primary) ; Pembrolizumab (Primary)
Indications Adenocarcinoma; Adenosquamous carcinoma; Biliary cancer; Cervical cancer; Cholangiocarcinoma; Colorectal cancer; Head and neck cancer; Solid tumours; Squamous cell cancer
Focus Adverse reactions; First in man; Therapeutic Use
Acronyms KEYNOTE-E34
Sponsors TiumBio

13 Feb 2025 Planned number of patients changed from 142 to 140.
04 Jun 2024 Results presented at the 60th Annual Meeting of the American Society of Clinical Oncology
01 Jun 2024 According to a TiumBio Media Release, interim results from the Phase 1b presented at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com